MXCT supply chain intelligence for MaxCyte, Inc.: verified suppliers, customers, debt relationships, acquisitions, and ownership data.
Data compiled by Redley Lamar · ChainSifter Intelligence
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| ONE-SUPPLIER | ONE-SUPPLIER | 90% | During the three months ended March 31, 2026 and 2025, 14% and 22% respectively, of the Company's additions to inventory were from one supplier |
| SECOND-SUPPLIER | SECOND-SUPPLIER | 90% | A second supplier accounted for 14% of accounts payable as of March 31, 2026 |
| BIO | Bio-Rad Laboratories, Inc. | 72% | Reciprocal relationship from BIO graph: Reciprocal relationship from MXCT graph: doption of our products. If these KOLs, institutions and companies do not adopt our products for any reason, including… |
| BIO | Bio-Rad Laboratories, Inc. | 72% | doption of our products. If these KOLs, institutions and companies do not adopt our products for any reason, including those listed above, acceptance and adoption of our products may be slowed and ou… |
| DTIL | Precision BioSciences, Inc. | 72% | ory approval for all or any product candidates covered by their SPL agreements with us, in which case we will not receive the full potential precommercial milestone payments or the sales-based commer… |
| DTIL | Precision BioSciences, Inc. | 72% | Reciprocal relationship from DTIL graph: Reciprocal relationship from MXCT graph: ory approval for all or any product candidates covered by their SPL agreements with us, in which case we will not rec… |
| HBIO | Harvard Bioscience, Inc. | 72% | doption of our products. If these KOLs, institutions and companies do not adopt our products for any reason, including those listed above, acceptance and adoption of our products may be slowed and ou… |
| HBIO | Harvard Bioscience, Inc. | 72% | Reciprocal relationship from HBIO graph: Reciprocal relationship from MXCT graph: Reciprocal relationship from HBIO graph: Reciprocal relationship from MXCT graph: doption of our products. If these K… |
| TGTX | TG Therapeutics, Inc. | 72% | ory approval for all or any product candidates covered by their SPL agreements with us, in which case we will not receive the full potential precommercial milestone payments or the sales-based commer… |
| TGTX | TG Therapeutics, Inc. | 72% | Reciprocal relationship from TGTX graph: Reciprocal relationship from MXCT graph: ory approval for all or any product candidates covered by their SPL agreements with us, in which case we will not rec… |
| TMO | Thermo Fisher Scientific Inc. | 72% | Reciprocal relationship from TMO graph: Reciprocal relationship from MXCT graph: Reciprocal relationship from TMO graph: Reciprocal relationship from MXCT graph: doption of our products. If these KOL… |
| TMO | Thermo Fisher Scientific Inc. | 72% | doption of our products. If these KOLs, institutions and companies do not adopt our products for any reason, including those listed above, acceptance and adoption of our products may be slowed and ou… |
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| USGOV-DEPARTMENT-OF-HEALTH-AND-HUMAN-SERVICES | USGOV-DEPARTMENT-OF-HEALTH-AND-HUMAN-SERVICES | 95% | USAspending awards from Department of Health and Human Services: $181,450 across 2 awards. 75N98026P00164 26-003578 MAXCYTE EXPERT GTX ELECTROPORATION DEVICE AND INSTALLATION/OPERATIONAL QUALIFICATIO… |
| USGOV-DEPARTMENT-OF-VETERANS-AFFAIRS | USGOV-DEPARTMENT-OF-VETERANS-AFFAIRS | 95% | USAspending awards from Department of Veterans Affairs: $49,680 across 1 awards. 36C24725P0739 MAXCYTE EXPERT ATX ELECTROPORATION SYSTEM | Qwen corrected direction: Explicit government contract award… |
| CELL-THERAPY-COMPANY | CELL-THERAPY-COMPANY | 92% | For the year ended December 31, 2025, one cell therapy company with which we have entered into an SPL agreement accounted for 26% of our total revenue |
| DTIL | Precision BioSciences, Inc. | 85% | ory approval for all or any product candidates covered by their SPL agreements with us, in which case we will not receive the full potential precommercial milestone payments or the sales-based commer… |
| DTIL | Precision BioSciences, Inc. | 85% | Reciprocal relationship from DTIL graph: Reciprocal relationship from MXCT graph: Reciprocal relationship from DTIL graph: Reciprocal relationship from MXCT graph: Reciprocal relationship from DTIL g… |
| IMUGENE-LIMITED | IMUGENE-LIMITED | 85% | pproval for all or any product candidates covered by their SPL agreements with us, in which case we will not receive the full potential precommercial milestone payments or the sales-based commercial … |
| TGTX | TG Therapeutics, Inc. | 85% | Reciprocal relationship from TGTX graph: Reciprocal relationship from MXCT graph: Reciprocal relationship from TGTX graph: Reciprocal relationship from MXCT graph: Reciprocal relationship from TGTX g… |
| TGTX | TG Therapeutics, Inc. | 85% | ory approval for all or any product candidates covered by their SPL agreements with us, in which case we will not receive the full potential precommercial milestone payments or the sales-based commer… |
| BIO | Bio-Rad Laboratories, Inc. | 72% | Reciprocal relationship from BIO graph: Reciprocal relationship from MXCT graph: Reciprocal relationship from BIO graph: Reciprocal relationship from MXCT graph: Reciprocal relationship from BIO grap… |
| BIO | Bio-Rad Laboratories, Inc. | 72% | doption of our products. If these KOLs, institutions and companies do not adopt our products for any reason, including those listed above, acceptance and adoption of our products may be slowed and ou… |
| HBIO | Harvard Bioscience, Inc. | 72% | Reciprocal relationship from HBIO graph: Reciprocal relationship from MXCT graph: doption of our products. If these KOLs, institutions and companies do not adopt our products for any reason, includin… |
| HBIO | Harvard Bioscience, Inc. | 72% | doption of our products. If these KOLs, institutions and companies do not adopt our products for any reason, including those listed above, acceptance and adoption of our products may be slowed and ou… |
| TMO | Thermo Fisher Scientific Inc. | 72% | Reciprocal relationship from TMO graph: Reciprocal relationship from MXCT graph: doption of our products. If these KOLs, institutions and companies do not adopt our products for any reason, including… |
| TMO | Thermo Fisher Scientific Inc. | 72% | doption of our products. If these KOLs, institutions and companies do not adopt our products for any reason, including those listed above, acceptance and adoption of our products may be slowed and ou… |
| Instrument | Description | Confidence | Evidence |
|---|---|---|---|
| MXCT-DEBT | Debt stack $17.5M | 90% | Market cache reports total debt of $17.5M. |
| MXCT-DEBT-11143 | Warrants outstanding: 71168 | 90% | xbrl warrant detail from xbrl 2021-12-31. |
| MXCT-DEBT-11144 | Xbrl Convertible | 90% | xbrl convertible detail from xbrl 2021-12-31. |
| Holder | Name | Confidence | Evidence |
|---|---|---|---|
| MXCT-OWNER-MORGAN-STANLEY | MORGAN STANLEY | 90% | 13F overlay lists MORGAN STANLEY as top holder; 131 tracked holders. |
| Ticker | Name | Chain Index | Hops | Relationship Types |
|---|---|---|---|---|
| SOLV | Solventum Corporation | 100.00 | 2 | |
| BHP | BHP Group Limited | 100.00 | 2 | |
| MGX | Metagenomi Therapeutics, Inc. | 100.00 | 2 | |
| FISI | Financial Institutions, Inc. | 100.00 | 2 | |
| BTAI | BioXcel Therapeutics, Inc. | 100.00 | 2 | |
| IMTX | Immatics N.V. | 100.00 | 2 | |
| BDX | Becton, Dickinson and Company | 100.00 | 2 | |
| TWST | Twist Bioscience Corporation | 100.00 | 2 | |
| IDXG | Interpace Biosciences, Inc. | 100.00 | 2 | |
| GH | Guardant Health, Inc. | 100.00 | 2 | |
| BHPLF | BHP Group Limited | 100.00 | 2 | |
| CLLS | Cellectis S.A. | 100.00 | 2 | |
| BIO | Bio-Rad Laboratories, Inc. | 100.00 | 1 | ['customer', 'supplier'] |
| CELU | Celularity Inc. | 100.00 | 2 | |
| HBIO | Harvard Bioscience, Inc. | 100.00 | 1 | ['customer', 'supplier'] |
| ICLR | ICON Public Limited Company | 100.00 | 2 | |
| TGTX | TG Therapeutics, Inc. | 100.00 | 1 | ['customer', 'supplier'] |
| AZTA | Azenta, Inc. | 100.00 | 2 | |
| FBIO | Fortress Biotech, Inc. | 100.00 | 2 | |
| IMDX | Insight Molecular Diagnostics Inc. | 100.00 | 2 |